Vaxcyte: Phase 3 Success for VAX-31: Protection Against 31 Bacterial Strains Causes Stock to Rise by 50%
Reading Time: 2 minutes
Vaxcyte targets prevention markets with protein conjugates. OPUS-1 data confirm the efficacy of VAX-31 in adults. The company is preparing for approvals in a multi-billion USD market. Protein Conjugates as an Economic Foundation Vaxcyte (PCVX) (i.) specializes in vaccines against bacterial infections through cell-free protein synthesis. The company benefits from the trend of health prevention, driven by an aging population and increasing antibiotic resistance. This technology allows for the bundling of more antigens in a single preparation...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
